Lunate Capital Ltd

Fundamental diversified ★Signal CIK 2056786
Long book
$120.4M
Q1 2026
Positions
6
Top-10 weight
100%
concentration
Last quarter
+54.5%
SPY +14.8%
Turnover
0%
of book per quarter

Strategy in plain words

auto-generated from filings

Lunate Capital Ltd is a diversified fundamental manager, running a $120.4M US long book across 6 positions.

The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: REVOLUTION MEDICINES INC, SAILPOINT INC, LINEAGE INC, NEUMORA THERAPEUTICS INC, NAVAN INC-CL A.

Over the last 5 quarters its long book ran on average 14.7pp per quarter ahead of the S&P 500, beating the index in 4 of 5 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.

Implied long-book return vs S&P 500

methodology: positions priced quarterly, no shorts/options
Fund long book S&P 500
Q1 2025
+3.6%
Q2 2025
+10.7%
Q3 2025
+30.8%
Q4 2025
+6.2%
Q1 2026
+54.5%

Sector allocation

Healthcare
58%
Technology
42%

Long book by quarter

$171.2M
Q1 2025
$178.1M
Q2 2025
$220.7M
Q3 2025
$264.3M
Q4 2025
$120.4M
Q1 2026

What does Lunate Capital own?

Q1 2026 13F
CompanySectorSharesValue% of bookChange
RVMD REVOLUTION MEDICINES INCHealthcare549.0K$53.4M44.4%-75.0%
SAIL SAILPOINT INCTechnology3.0M$39.7M33.0%Held
NMRA NEUMORA THERAPEUTICS INCHealthcare2.1M$4.1M3.4%Held
NAVN NAVAN INC-CL ATechnology200.0K$2.6M2.2%Held

13F filing history

PeriodFormFiledEntriesReported valueFlagsSource
Q1 202613F-HRApr 16, 20266$120.4M canonicalSEC ↗
Q4 202513F-HRJan 23, 20266$264.3M canonicalSEC ↗
Q3 202513F-HR/ARESTATEMENTNov 20, 20256$220.7M canonicalSEC ↗
Q3 202513F-HRNov 10, 202510$1.20B SEC ↗
Q2 202513F-HRJul 17, 20256$178.1M canonicalSEC ↗
Q1 202513F-HRApr 25, 20254$171.2M canonicalSEC ↗